GlassScriptPhysician profile
Megan Reingold
NPI 1285325936
$2,323.43
in general payments reported to CMS, 2019-2025
21 companies · $1,212 in 2025
The $1,212 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $21.99 · 2024: $1,089 · 2025: $1,212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,183 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,183.44 |
| Education | $139.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $370.53 | 2024-2025 | |
| Janssen Biotech, INC. | $317.89 | 2024-2025 | Tremfya |
| Lilly USA, LLC | $304.96 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| Abbvie INC. | $294.39 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $270.14 | 2025 | Zoryve |
| Genzyme Corporation | $133.29 | 2024 | |
| Novartis Pharmaceuticals Corporation | $91.29 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $90.04 | 2024-2025 | Dupixent |
| Galderma Laboratories, L.P. | $76.17 | 2024-2025 | Nemluvio, Aklief |
| Incyte Corporation | $57.12 | 2025 | Opzelura |
| Ucb, INC. | $53.36 | 2024-2025 | Bimzelx |
| Organogenesis INC. | $47.45 | 2024 | |
| Smith+Nephew, INC. | $43.58 | 2024 | Grafix Pl |
| Organon LLC | $25.67 | 2025 | |
| Dermavant Sciences, INC. | $25.38 | 2024 | Vtama |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.33 | 2024 | Cabtreo |
| Amgen INC. | $21.99 | 2023 | Otezla |
| Pfizer INC. | $20.77 | 2025 | |
| Biofrontera INC. | $19.52 | 2024 | Rhodoled Xl, Ameluz, Xepi |
| Leo Pharma INC. | $19.16 | 2024 | Adbry |
| Journey Medical Corporation | $18.40 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Reingold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.